MedPath

Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome

Not Applicable
Conditions
Polycystic Ovary Syndrome
Registration Number
NCT00319293
Lead Sponsor
Aarhus University Hospital Skejby
Brief Summary

Insulin resistance is an important feature of the polycystic ovary syndrome,and patiens are successfully treated with the insulin sensitizing agent metformin. The insulin resistance of lean patients with the syndrome is debated. In this study, we will study the change in insulin resistance, metabolic and hormonal factors after 3 months of metformin treatment in lean PCOS women.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • PCOS (Rotterdam criteria)
  • BMI < 27
  • No medication for 3 months
Exclusion Criteria
  • Pregnancy
  • Lactation
  • Other endocrinologic disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Insulin resistance
Hormonal factors
Metabolic factors
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath